Bioavailability Enhancement of Polymyxin B With Novel Drug Delivery: Development and Optimization Using Quality-by-Design Approach

Chauhan, Meenakshi Kanwar; Bhatt, Nidhi

doi:10.1016/j.xphs.2018.11.032

Cited by 30 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They protected polymyxin B from the GIT environment and increased its absorption within the normal limits of nephrotoxicity, indicating that niosomes improve the oral bioavailability of polymyxin B. There is no increase in the side effects with this mode of delivery [ 213 ]. Therefore, the improved delivery and actions of polymyxins shall be obtained by a blend of chemistry, nanotechnology, and pharmaceutics.…”

Section: Future Implicationsmentioning

confidence: 99%

Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance

2020

View full text Add to dashboard Cite

Following their initial discovery in the 1940s, polymyxin antibiotics fell into disfavor due to their potential clinical toxicity, especially nephrotoxicity. However, the dry antibiotic development pipeline, together with the rising global prevalence of infections caused by multidrug-resistant (MDR) Gram-negative bacteria have both rejuvenated clinical interest in these polypeptide antibiotics. Parallel to the revival of their use, investigations into the mechanisms of action and resistance to polymyxins have intensified. With an initial known effect on biological membranes, research has uncovered the detailed molecular and chemical interactions that polymyxins have with Gram-negative outer membranes and lipopolysaccharide structure. In addition, genetic and epidemiological studies have revealed the basis of resistance to these agents. Nowadays, resistance to polymyxins in MDR Gram-negative pathogens is well elucidated, with chromosomal as well as plasmid-encoded, transferrable pathways. The aims of the current review are to highlight the important chemical, microbiological, and pharmacological properties of polymyxins, to discuss their mechanistic effects on bacterial membranes, and to revise the current knowledge about Gram-negative acquired resistance to these agents. Finally, recent research, directed towards new perspectives for improving these old agents utilized in the 21st century, to combat drug-resistant pathogens, is summarized.

show abstract

Section: Future Implicationsmentioning

confidence: 99%

Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance

2020

View full text Add to dashboard Cite

show abstract

“…Polymyxin B, produced by the bacterium Bacillus polymyxa, belongs to the group of cyclic peptide antibiotics and is used to treat infections caused mainly by Gram-negative bacteria (Chauhan and Bhatt, 2019). Polymixin B cross-linked with sodium alginate and polyion complex nanoparticles or niosomes loaded with polymixin B showed potent antimicrobial activity against Pseudomonas aeruginosa (Severino et al, 2015;Insua et al, 2017;Chauhan and Bhatt, 2019). Amphotericin B is isolated from Streptomyces nodosus and is an antifungal drug used for severe fungal infections such as aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis and is also a generic drug for leishmaniasis, which is caused by parasites of the genus Leishmania.…”

Section: Nanocarriers As Drug Delivery Systemsmentioning

confidence: 99%

“…Nano delivery also enhances the antibacterial efficacy of classical antibiotics and antifungals, while reducing their toxicity and allowing repurposing for viral infections. Polymyxin B, produced by the bacterium Bacillus polymyxa, belongs to the group of cyclic peptide antibiotics and is used to treat infections caused mainly by Gram-negative bacteria ( Chauhan and Bhatt, 2019 ). Polymixin B cross-linked with sodium alginate and polyion complex nanoparticles or niosomes loaded with polymixin B showed potent antimicrobial activity against Pseudomonas aeruginosa ( Severino et al, 2015 ; Insua et al, 2017 ; Chauhan and Bhatt, 2019 ).…”

Section: Natural Products With Antiviral Activitymentioning

confidence: 99%

Natural Compounds With Antimicrobial and Antiviral Effect and Nanocarriers Used for Their Transportation

Stan

Enciu

Mateescu³

et al. 2021

Front. Pharmacol.

120

View full text Add to dashboard Cite

Due to the increasing prevalence of life-threatening bacterial, fungal and viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compunds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable compounds for this task are usually derived from natural sources (animal, plant or even microbial). In this review article, the latest and most promising natural compounds used to combat bacteria, filamentous fungi and viruses are presented and evaluated. These include plant extracts, essential oils, small antimicrobial peptides of animal origin, bacteriocins and various groups of plant compounds (triterpenoids; alkaloids; phenols; flavonoids) with antimicrobial and antiviral activity. Data are presented on the inhibitory activity of each natural antimicrobial substance and on the putative mechanism of action against bacterial and fungal strains. The results show that among the bioactive compounds studied, triterpenoids have significant inhibitory activity against coronaviruses, but flavonoids have also been shown to inhibit SARS-COV-2. The last chapter is devoted to nanocarriers used to improve stability, bioavailability, cellular uptake/internalization, pharmacokinetic profile and reduce toxicity of natural compunds. There are a number of nanocarriers such as liposomes, drug delivery microemulsion systems, nanocapsules, solid lipid nanoparticles, polymeric micelles, dendrimers, etc. However, some of the recent studies have focused on the incorporation of natural substances with antimicrobial/antiviral activity into polymeric nanoparticles, niosomes and silver nanoparticles (which have been shown to have intrinsic antimicrobial activity). The natural antimicrobials isolated from animals and microorganisms have been shown to have good inhibitory effect on a range of pathogens, however the plants remain the most prolific source. Even if the majority of the studies for the biological activity evaluation are in silico or in vitro, their internalization in the optimum nanocarriers represents the future of “green therapeutics” as shown by some of the recent work in the field.

show abstract

“…Ex vivo toxicity against liver cells obtained from sacrificed rats was similar for these niosomes compared to a polymyxin B solution. Most importantly, pharmacokinetic studies in rats revealed that an oral dose of 2 mg/kg of polymyxin B niosomes enhanced AMP content in intestines of rats and stimulated crossing the GIT through transcytosis of M-cells in the intestine, resulting in systemic circulation of the drug compared to intravenous injection of polymyxin B sulfate [56]. Therefore, niosomes could provide the necessary stability in the GIT for oral delivery of AMPs.…”

Section: Niosomesmentioning

confidence: 99%

Current Advances in Lipid and Polymeric Antimicrobial Peptide Delivery Systems and Coatings for the Prevention and Treatment of Bacterial Infections

et al. 2021

View full text Add to dashboard Cite

Bacterial infections constitute a threat to public health as antibiotics are becoming less effective due to the emergence of antimicrobial resistant strains and biofilm and persister formation. Antimicrobial peptides (AMPs) are considered excellent alternatives to antibiotics; however, they suffer from limitations related to their peptidic nature and possible toxicity. The present review critically evaluates the chemical characteristics and antibacterial effects of lipid and polymeric AMP delivery systems and coatings that offer the promise of enhancing the efficacy of AMPs, reducing their limitations and prolonging their half-life. Unfortunately, the antibacterial activities of these systems and coatings have mainly been evaluated in vitro against planktonic bacteria in less biologically relevant conditions, with only some studies focusing on the antibiofilm activities of the formulated AMPs and on the antibacterial effects in animal models. Further improvements of lipid and polymeric AMP delivery systems and coatings may involve the functionalization of these systems to better target the infections and an analysis of the antibacterial activities in biologically relevant environments. Based on the available data we proposed which polymeric AMP delivery system or coatings could be profitable for the treatment of the different hard-to-treat infections, such as bloodstream infections and catheter- or implant-related infections.

show abstract

Bioavailability Enhancement of Polymyxin B With Novel Drug Delivery: Development and Optimization Using Quality-by-Design Approach

Cited by 30 publications

References 27 publications

Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance

Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance

Natural Compounds With Antimicrobial and Antiviral Effect and Nanocarriers Used for Their Transportation

Current Advances in Lipid and Polymeric Antimicrobial Peptide Delivery Systems and Coatings for the Prevention and Treatment of Bacterial Infections

Contact Info

Product

Resources

About